ArticleiGIE : innovation, investigation and insights2022
Efficacy, feasibility, and safety of endoscopic double closure in the GI tract.
Article in iGIE : innovation, investigation and insights, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endoscopic closure is an important technique with prophylactic and therapeutic indications. In certain situations, performing a dual-modality closure might be justified over using a single-closure modality to achieve a more secure closure or to close a large defect more efficiently. Here we present 6 cases where dual-modality closure was used in a variety of indications in the upper and lower GI tracts. Efficacy was noted in all cases, and no adverse events were seen. This work highlights the feasibility, versatility, and safety of dual-modality closure using the endoscopic Helix Tacking System (X-Tack; Apollo Endosurgery, Austin, Tex, USA) to facilitate dual-modality closure in a variety of indications such as persistent gastrocutaneous fistulas and prevention of delayed bleeding after resection of high-risk lesions. Head-to-head prospective studies are needed to compare the outcomes and cost-effectiveness of dual-modality closure versus single-modality closure.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.